Large Outflow of Money Witnessed in Astrazeneca PLC

Astrazeneca PLC (AZN) : Net money flow in Astrazeneca PLC (AZN) was negative ($1.14 million) and the inflow of money on uptick was $0.43 million, whereas, the outflow of money on downticks amounted to $1.57 million on Wednesday. The traders used every opportunity of price strength in the stock to sell their positions, hence, the total uptick to downtick ratio was 0.28. The block trades show that the large investors, were aggressive sellers in the stock. On the other hand, the total value of block trades done on downticks was $0.9 million. The money flow in block trades was negative ($0.9). Astrazeneca PLC (AZN) gained $0.42 cent during the day and reached $34.03, a gain of 1.25% over the previous day.

Astrazeneca

Shares of AstraZeneca PLC rose by 0.21% in the last five trading days and 1.56% for the last 4 weeks. AstraZeneca PLC is up 14.81% in the last 3-month period. Year-to-Date the stock performance stands at 4.21%.

Astrazeneca PLC (AZN) : The consensus on Astrazeneca PLC (AZN) based on 4 analyst recommendation on the company stock is 2, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Astrazeneca PLC (NYSE:AZN): The stock opened at $33.99 and touched an intraday high of $34.09 on Wednesday. During the day, the stock corrected to an intraday low of $33.73, however, the bulls stepped in and pushed the price higher to close in the green at $33.82 with a gain of 0.62% for the day. The total traded volume for the day was 8,517,959. The stock had closed at $33.61 in the previous trading session.

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.